Update

Press Release

November 22, 2017 Launched
Chordia Therapeutics Inc. (“Chordia”) was launched in Shonan Health Innovation Park at Takeda Pharmaceutical Company Limited (“Takeda”) Shonan site. Chordia seeks to discover new therapeutic options for areas of high unmet medical needs in oncology.
The newly formed company will develop multiple preclinical assets licensed from Takeda, including CDC-like kinase (“CLK”) inhibitors. Chordia uses fully-equipped laboratory space and other resources at Takeda’s Health Innovation Park to support efficient drug research and development. Chordia was established by six former Takeda scientists through the Takeda Entrepreneurship Venture Program (“EVP”) initiative. The EVP initiative was created to promote innovation and an environment of entrepreneurship by combining selected Takeda assets or technologies and outstanding scientists with start-up support.